CIq Affinity Measurement of Recombinant Protein Drugs

Recombinant protein drugs refer to protein products originating from animals or plants and developed through biotechnology research, which have certain biological activities and can prevent, treat, and diagnose human, animal, and plant diseases. Compared to small molecule drugs, recombinant protein drugs have advantages such as high activity, high specificity, and low toxicity, hence they are favored by many researchers. Currently, recombinant protein drugs are widely used in various fields such as tumors, autoimmune diseases, metabolic diseases, geriatric diseases, and degenerative diseases. CIq affinity determination is a technique for measuring the interaction between recombinant protein drugs and CIq. CIq is a component of our immune system, and its interaction with drugs may lead to adverse reactions or affect the efficacy of the drug. Through CIq affinity determination, we can evaluate whether recombinant protein drugs will bind with CIq and the strength of their binding.

 

This technology is crucial to the safety and effect evaluation of drugs. If a drug binds too strongly with CIq, it may cause adverse reactions such as the formation of immune complexes or the activation of the complement system. Conversely, if a drug has weak or no binding with CIq, then the drug might be safer and less likely to cause adverse reactions. Currently, there are mainly three mainstream technologies for CIq affinity determination: Surface Plasmon Resonance (SPR), Bio-Layer Interferometry (BLI), and Competitive ELISA for affinity testing.

 

The SPR affinity determination method mainly utilizes light to generate evanescent waves and plasmon waves in different media to construct the interaction of biomolecules, which is used to detect the interaction between the ligand and the analyte on the biosensor chip. BLI is a label-free and real-time optical detection technology that can monitor the binding process of the entire molecule in real time. It uses a fiber optic biosensor to monitor the change in the optical layer thickness of the sensor when the molecules bind and dissociate. Compared with other technologies such as ELISA and Co-Immunoprecipitation, SPR and BLI have significant advantages such as real-time, label-free, and being able to detect low affinity, and being widely used in biopharmaceutical affinity determination.

 

MtoZ Biolabs laboratory provides you with fast and accurate recombinant protein drug CIq affinity determination services based on our existing experimental platform. Feel free to consult us for free.